IGF-1: When to Order This Test and What the Results Mean

What Does IGF-1 Mean?

IGF-1 stands for insulin-like growth factor 1, a 70-amino-acid peptide hormone produced mainly in the liver under direct stimulation by pituitary growth hormone. It mediates most of the anabolic and metabolic effects people associate with GH itself, including lean-mass accrual, bone mineralization, collagen synthesis, and glucose regulation. Because GH is released in short, pulsatile bursts (primarily during slow-wave sleep), a single random GH blood draw is almost useless for clinical decision-making 1. IGF-1, by contrast, circulates bound to carrier proteins (chiefly IGFBP-3) with a half-life of roughly 12 to 15 hours, providing a stable, integrated readout of the previous day's GH output.

The 2011 Endocrine Society Clinical Practice Guideline states: "Serum IGF-1 is the most useful single screening test for suspected GH disorders in adults and children" 1. That guideline positions IGF-1 as the gatekeeper: if IGF-1 falls within the age-adjusted reference range and clinical suspicion is low, dynamic GH stimulation testing can often be deferred. A low IGF-1 plus compatible symptoms (fatigue, truncal adiposity, reduced exercise capacity) triggers confirmatory testing with insulin tolerance test (ITT) or glucagon stimulation test 2.

Think of IGF-1 as the GH axis thermostat reading. It does not tell you exactly when GH was secreted, but it tells you whether the system produced enough over the past 24 hours.

When to Order an IGF-1 Test

The short answer: order IGF-1 whenever you need to evaluate or monitor GH-axis function. Specific clinical scenarios fall into three categories.

Diagnostic workup. IGF-1 is first-line when a patient presents with signs of GH deficiency (increased visceral fat, low bone density, impaired quality of life after pituitary surgery or radiation) or GH excess (coarsened facial features, enlarged hands, new-onset diabetes). The AACE 2019 consensus on acromegaly management recommends IGF-1 as the initial biochemical screen, followed by oral glucose tolerance with GH nadir measurement if IGF-1 is elevated 3. In a validation cohort of 1,485 patients with suspected acromegaly, an elevated age-adjusted IGF-1 had a sensitivity of 97% and specificity of 95% for active disease 4.

Therapy monitoring. For patients receiving GH replacement (somatropin) or GH-secretagogue peptides (sermorelin, tesamorelin, CJC-1295/ipamorelin), the Endocrine Society recommends checking IGF-1 at baseline, 1 month after dose initiation, and every 3 to 6 months during maintenance 1. The target is typically the upper half of the age-adjusted normal range without exceeding the upper limit of normal (ULN). A 2009 consensus statement from nine endocrine societies reinforced this target: "IGF-1 levels should be maintained within the age-appropriate normal range, aiming for the mid-to-upper normal range to optimize clinical benefit" 2.

Longevity and preventive screening. Some longevity-focused clinicians order baseline IGF-1 in adults over 35 as part of an expanded hormone panel, particularly when evaluating body composition changes, declining exercise recovery, or sarcopenia risk. While no major guideline endorses population-wide IGF-1 screening, the test provides context that isolated testosterone or thyroid panels miss.

Normal IGF-1 Range by Age

IGF-1 peaks during puberty and declines roughly 14% per decade after age 30 5. Interpreting a result without age-matching is a common clinical error.

Approximate adult reference ranges (median laboratory assays, ng/mL):

| Age Range | Females (ng/mL) | Males (ng/mL) | |-----------|-----------------|---------------| | 18-25 | 170-390 | 180-400 | | 26-35 | 130-340 | 140-360 | | 36-45 | 110-290 | 120-310 | | 46-55 | 90-250 | 95-270 | | 56-65 | 75-220 | 80-240 | | 66-75 | 60-200 | 65-210 | | 76+ | 50-180 | 55-190 |

These ranges can vary between laboratories because IGF-1 immunoassays are not yet fully standardized. The 2019 international consensus on IGF-1 assay harmonization (Bidlingmaier et al.) found inter-assay coefficient of variation as high as 30% across six commercial platforms 6. The practical takeaway: always compare serial results drawn at the same lab using the same assay.

A 55-year-old male with IGF-1 of 130 ng/mL sits near the middle of his age bracket. That same value in a 25-year-old male would fall well below the 10th percentile and warrant further investigation.

What a High IGF-1 Level Means

An IGF-1 above the age-adjusted upper limit raises two distinct clinical questions: is there autonomous GH hypersecretion (acromegaly), or is exogenous therapy overshooting?

Acromegaly. GH-secreting pituitary adenomas affect roughly 3 to 14 per 100,000 people, but diagnosis is often delayed 7 to 10 years from symptom onset 3. Persistently elevated IGF-1 with a GH nadir above 1 ng/mL on oral glucose tolerance test confirms the diagnosis. Left untreated, acromegaly increases cardiovascular mortality two- to threefold 7.

Therapy overshoot. Patients on GH replacement or peptide therapy whose IGF-1 exceeds the ULN may experience fluid retention, joint stiffness, carpal tunnel symptoms, and insulin resistance. The Endocrine Society guideline recommends dose reduction to bring IGF-1 back within range 1. A practical rule: if IGF-1 sits more than 10% above the ULN on two consecutive draws spaced 4 weeks apart, lower the dose by 20 to 25%.

Cancer risk signal. Epidemiologic data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (N=520,000) found that individuals in the highest quintile of circulating IGF-1 had a 1.24 relative risk (95% CI 1.09-1.42) for colorectal cancer compared with the lowest quintile 8. The association does not prove causation. It does mean that chronic, supra-physiologic IGF-1 should be avoided, especially in patients with first-degree relatives who have GI malignancies.

What a Low IGF-1 Level Means

Low IGF-1 can reflect GH deficiency, malnutrition, liver dysfunction, or poorly controlled type 1 diabetes. Context determines which path to investigate.

Adult GH deficiency (AGHD). The condition affects an estimated 1 in 3,000 to 10,000 adults, including survivors of pituitary tumors, traumatic brain injury, or cranial irradiation 2. Symptoms are nonspecific: fatigue, abdominal adiposity, reduced lean mass, poor sleep quality, decreased bone mineral density. IGF-1 in the lower third of the age-adjusted range paired with two or more of these symptoms should prompt confirmatory stimulation testing. The insulin tolerance test remains the gold standard, though the glucagon stimulation test and macimorelin test (FDA-approved 2017) are alternatives 9.

Nutritional suppression. Caloric restriction, eating disorders, and protein malnutrition all reduce hepatic IGF-1 synthesis independent of GH status. A study of 62 patients with anorexia nervosa found mean IGF-1 of 78 ng/mL, roughly 55% below age-matched controls 10. Refeeding normalized levels within 6 to 8 weeks, confirming the suppression was nutritional rather than pituitary in origin.

Hepatic impairment. Because the liver produces approximately 75% of circulating IGF-1, advanced cirrhosis or severe hepatitis can drive levels below the measurable range even when GH secretion is normal or elevated (a state called GH resistance). Checking hepatic function alongside IGF-1 helps avoid a false diagnosis of GH deficiency.

How to Raise IGF-1

Raising IGF-1 is appropriate only when the level is confirmed low on the age-adjusted scale and a clinical indication exists. The approach depends on the cause.

GH replacement therapy. For confirmed AGHD, recombinant human GH (somatropin) remains the standard treatment. Starting doses are typically 0.2 to 0.4 mg/day in adults, titrated by IGF-1 response every 4 to 8 weeks 1. Women on oral estrogen may require higher doses because first-pass hepatic metabolism blunts GH-to-IGF-1 conversion.

GH-secretagogue peptides. Growth-hormone-releasing-hormone (GHRH) analogues like sermorelin and tesamorelin, plus receptor secretagogues like CJC-1295/ipamorelin, stimulate endogenous GH release from the pituitary. Tesamorelin is the best-studied option: a 26-week randomized controlled trial (N=412) demonstrated a mean IGF-1 increase of 81 ng/mL from baseline with simultaneous reduction in visceral adipose tissue 11. These peptides carry lower risk of IGF-1 overshoot than exogenous GH because the pituitary retains negative-feedback regulation.

Sleep optimization. GH secretion concentrates in slow-wave sleep. A landmark study by Van Cauter et al. showed that men sleeping 4 hours versus 8 hours had 70% lower overnight GH area-under-the-curve 12. Sleep hygiene (consistent schedule, dark room, no alcohol within 3 hours of bed) is the lowest-cost intervention for a borderline-low IGF-1.

Resistance training. Compound, heavy-load exercises (squats, deadlifts, rows) acutely raise GH by 300 to 500% in the 15 to 30 minutes post-set 13. Over 12 weeks, trained individuals show a modest but measurable rise in resting IGF-1 of approximately 10 to 15%.

Adequate protein. Protein intake below 0.8 g/kg/day limits hepatic IGF-1 production. Increasing intake to 1.2 to 1.6 g/kg/day (the range recommended by the International Society of Sports Nutrition for active adults) supports IGF-1 recovery, especially in older adults with sarcopenia 14.

How to Lower IGF-1

Lowering IGF-1 matters in two scenarios: confirmed acromegaly and intentional GH-axis modulation in longevity medicine.

Acromegaly treatment. First-line medical therapy is a somatostatin receptor ligand (SRL) such as octreotide LAR or lanreotide depot. In a pooled analysis of 619 acromegaly patients, SRL therapy normalized IGF-1 in 55% of subjects within 12 months 15. Pegvisomant, a GH receptor antagonist, normalizes IGF-1 in approximately 90% of patients but does not shrink the adenoma 3.

Dose reduction of exogenous GH or peptides. The simplest lever. If a patient on sermorelin or somatropin has IGF-1 above the ULN, decreasing the dose by 20 to 25% and rechecking at 4 to 6 weeks is standard practice.

Dietary and lifestyle approaches. Caloric restriction and low-glycemic-index diets reduce fasting insulin, which in turn downregulates hepatic IGF-1 receptor sensitivity. Intermittent fasting protocols (16:8 or 5:2 patterns) have shown 10 to 20% reductions in circulating IGF-1 in short-term studies, though long-term data are limited 16. For patients with borderline-high IGF-1 and no pathology, these dietary adjustments are reasonable first steps before pharmacologic intervention.

Dr. Laurence Katznelson, Professor of Neurosurgery and Medicine at Stanford and lead author of the AACE acromegaly guidelines, has noted: "The goal of treatment is to normalize IGF-1 for age and sex, reduce tumor mass, and reverse or prevent comorbidities such as cardiovascular disease and diabetes" 3.

Practical Ordering Tips

Getting the most out of an IGF-1 draw requires attention to a few technical details that many clinicians overlook.

Timing. Morning draws (before 10 AM) reduce diurnal variability, though the effect is less pronounced for IGF-1 than for cortisol or testosterone. Fasting is not required, but consistency matters: if the baseline was fasting at 8 AM, follow-ups should match.

Concurrent labs. Order IGF-1 alongside IGFBP-3 when evaluating suspected GH deficiency. The IGF-1/IGFBP-3 molar ratio improves diagnostic accuracy in patients with borderline results 5. Also consider a comprehensive metabolic panel (to rule out hepatic suppression), HbA1c (uncontrolled diabetes suppresses IGF-1), and a lipid panel (GH deficiency often presents with elevated LDL).

Assay consistency. Stick with one laboratory for serial monitoring. Switching between platforms (Immulite, iSYS, LIAISON) can introduce shifts of 30 to 80 ng/mL on the same sample 6.

Documentation. Record the patient's age, sex, BMI, and assay platform alongside every IGF-1 result. These variables all shift the reference range, and a result that looks "normal" in isolation may be abnormal once these factors are accounted for.

Monitoring cadence on therapy. Baseline, 4 weeks post-initiation, then every 3 to 6 months during stable dosing. If a dose change occurs, recheck at 4 to 6 weeks. Annual monitoring is sufficient for patients on stable GH or peptide therapy whose last three values were within range.